These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11266737)

  • 1. Mixed bone marrow chimerism as a treatment for autoimmune diabetes.
    Leykin I; Nikolic B; Sykes M
    Transplant Proc; 2001; 33(1-2):120. PubMed ID: 11266737
    [No Abstract]   [Full Text] [Related]  

  • 2. Chimerism-induced remission of overt diabetes in nonobese diabetic mice.
    Li H; Inverardi L; Ricordi C
    Transplant Proc; 1999; 31(1-2):640. PubMed ID: 10083274
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction of mixed bone marrow chimerism as potential therapy for autoimmune (type I) diabetes: experience in the NOD model.
    Mathieu C; Bouillon R; Rutgeerts O; Waer M
    Transplant Proc; 1995 Feb; 27(1):640-1. PubMed ID: 7879129
    [No Abstract]   [Full Text] [Related]  

  • 4. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice.
    Li H; Kaufman CL; Boggs SS; Johnson PC; Patrene KD; Ildstad ST
    J Immunol; 1996 Jan; 156(1):380-8. PubMed ID: 8598488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmyeloablative bone marrow transplantation based on deletion of host-anti-donor alloreactive cells prevents autoimmune insulitis and diabetes in nonobese diabetic mice.
    Elkin G; Prighozina TB; Gurevitch O; Slavin S
    Transplant Proc; 2002 Jun; 34(4):1303-6. PubMed ID: 12072346
    [No Abstract]   [Full Text] [Related]  

  • 6. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity.
    Nikolic B; Takeuchi Y; Leykin I; Fudaba Y; Smith RN; Sykes M
    Diabetes; 2004 Feb; 53(2):376-83. PubMed ID: 14747288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against autoimmune diabetes by induction of mixed bone marrow chimerism.
    Mathieu C; Vandeputte M; Bouillon R; Waer M
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1266-7. PubMed ID: 8442108
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of either split tolerance or robust tolerance along with humoral tolerance to donor and third-party alloantigens in nonmyeloablative mixed chimeras.
    Chan WF; Razavy H; Luo B; Shapiro AM; Anderson CC
    J Immunol; 2008 Apr; 180(8):5177-86. PubMed ID: 18390699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed chimerism.
    Sykes M; Sachs DH
    Philos Trans R Soc Lond B Biol Sci; 2001 May; 356(1409):707-26. PubMed ID: 11375074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary on "Optimizing chimerism level through bone marrow transplantation and irradiation to induce long-term tolerance to composite tissue allotransplantation".
    Tsoulfas G
    J Surg Res; 2013 Nov; 185(1):e59-60. PubMed ID: 22656036
    [No Abstract]   [Full Text] [Related]  

  • 11. MHC class II compatibility between donor bone marrow and secondary organ grafts is required for tolerance based on mixed chimerism.
    Jäger MD; Tsui T; Timrott K; Aselmann H; Deiwick A; Neipp M; Wonigeit K; Klempnauer J; Schlitt HJ
    Transplant Proc; 2001; 33(1-2):176. PubMed ID: 11266766
    [No Abstract]   [Full Text] [Related]  

  • 12. MHC-mismatched chimerism is required for induction of transplantation tolerance in autoimmune nonobese diabetic recipients.
    Wang M; Racine J; Zhang M; Wu T; Deng R; Johnston H; Shen C; Siswanto K; Zeng D
    J Immunol; 2014 Aug; 193(4):2005-15. PubMed ID: 25000982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of donor-specific tolerance in a skin transplantation model.
    van Pel M; Vingerhoed J; de Vries-van der Zwan A; van der Pol MA; Boog CJ
    Transplant Proc; 2001; 33(1-2):152-3. PubMed ID: 11266754
    [No Abstract]   [Full Text] [Related]  

  • 14. Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection.
    Metzler B; Gfeller P; Bigaud M; Li J; Wieczorek G; Heusser C; Lake P; Katopodis A
    J Immunol; 2004 Dec; 173(11):7025-36. PubMed ID: 15557200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against autoimmune diabetes in mixed bone marrow chimeras: mechanisms involved.
    Mathieu C; Casteels K; Bouillon R; Waer M
    J Immunol; 1997 Feb; 158(3):1453-7. PubMed ID: 9013991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing chimerism level through bone marrow transplantation and irradiation to induce long-term tolerance to composite tissue allotransplantation.
    Tetteh HA
    J Surg Res; 2013 Aug; 183(2):544-5. PubMed ID: 22677610
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.
    Elkin G; Prigozhina TB; Slavin S
    Exp Hematol; 2004 Jun; 32(6):579-84. PubMed ID: 15183899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing chimerism level through bone marrow transplantation and irradiation to induce long-term tolerance to composite tissue allotransplantation.
    Lin JY; Tsai FC; Wallace CG; Huang WC; Wei FC; Liao SK
    J Surg Res; 2012 Nov; 178(1):487-93. PubMed ID: 22484382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of mixed chimerism depletes pre-existing and de novo-developed autoreactive B cells in autoimmune NOD mice.
    Racine JJ; Wang M; Zhang M; Zeng D
    Diabetes; 2014 Jun; 63(6):2051-62. PubMed ID: 24458357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning.
    Luo B; Nanji SA; Schur CD; Pawlick RL; Anderson CC; Shapiro AM
    Transplantation; 2005 Aug; 80(3):370-7. PubMed ID: 16082333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.